Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar sodium versus silymarin in type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease
ChiCTR2500099866Phase 4Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of chiglitazar and silymarin in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Liver fat content at 48 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
chiglitazarsilymarin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2500099866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099866.